Guardion Health Sciences Announces Financial Results for the Year Ended December 31, 2023
29 mars 2024 06h15 HE
|
Guardion Health Sciences, Inc.
Viactiv® Product Line Generated Net Revenues of Approximately $11.9 Million for the Year Ended December 31, 2023, an Increase of Approximately 12% as Compared to the Year Ended December 31, 2022 ...
Guardion Health Sciences Announces Entry into Definitive Agreement to Sell its Well-Known Viactiv® Brand and Business to Doctor’s Best Inc.
30 janv. 2024 18h13 HE
|
Guardion Health Sciences, Inc.
HOUSTON, TEXAS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”) announced today that it has signed an equity purchase agreement to sell...
Guardion Health Sciences Announces Financial Results for the Three Months and Nine Months Ended September 30, 2023
13 nov. 2023 16h10 HE
|
Guardion Health Sciences, Inc.
Viactiv® Generated Net Revenues of Approximately $3.3 Million for the Three Months Ended September 30, 2023, an increase of 27% over the Three Months Ended September 30, 2022 HOUSTON, TEXAS, Nov. ...
Guardion Health Sciences, Inc. Announces Proposed Public Offering
17 févr. 2022 09h00 HE
|
Guardion Health Sciences, Inc.
HOUSTON, TEXAS, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) (“Guardion” or the “Company”), a clinical nutrition company that develops clinically supported...
Guardion Provides Answers to Frequently Asked Questions Regarding the Reasons for Approving the Reverse Stock Split Proposal at Upcoming 2020 Annual Stockholders’ Meeting
27 oct. 2020 08h30 HE
|
Guardion Health Sciences, Inc.
SAN DIEGO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (NASDAQ: GHSI) is providing the following answers to frequently asked questions to its...
Guardion Provides Answers to Frequently Asked Questions Regarding the Reasons for Approving the Reverse Stock Split Proposal at Upcoming 2020 Annual Stockholders’ Meeting
27 oct. 2020 08h30 HE
|
Guardion Health Sciences, Inc.
SAN DIEGO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (NASDAQ: GHSI) is providing the following answers to frequently asked questions to its...
Guardion Announces Virtual Annual Meeting of Stockholders
11 sept. 2020 17h20 HE
|
Guardion Health Sciences, Inc.
Annual stockholder meeting scheduled for Thursday, October 29, 2020 San Diego, California, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc.(“Guardion” or the...
Guardion Subsidiary VectorVision Receives Approval from Korean Intellectual Property Office for CSV-2000 Trademark
15 juil. 2020 09h00 HE
|
Guardion Health Sciences, Inc.
The Only Computer Vision Testing Device to Combine Standardized Contrast Sensitivity Testing with a Full Suite of Clinical Vision Tests San Diego, California, July 15, 2020 (GLOBE NEWSWIRE) --...
Guardion Health Sciences Announces Submission of Patent Application for Treatment of Certain Underlying Conditions Related to Eye Disease
08 juil. 2020 08h45 HE
|
Guardion Health Sciences, Inc.
Patent Application Will Add to Guardion’s Intellectual Property Portfolio San Diego, California, July 08, 2020 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”)...
Guardion Health Sciences Names Dr. David Evans as Interim President and Interim Chief Executive Officer
15 juin 2020 16h20 HE
|
Guardion Health Sciences, Inc.
San Diego, California, June 15, 2020 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI) announced today that its Board of Directors has appointed Dr....